Ora visual navigation course™ mobility test results in two individuals with CEP290 LCA after intravitreal injection of antisense oligonucleotide
Authors:
- Caio MarquesCMCaio Marques
- Gabriela Doná RodriguesGRGabriela Doná Rodrigues
- Cristina MuccioliCMCristina Muccioli
- Adriana BerezovskyABAdriana Berezovsky
- Nívea Nunes FerrazNFNívea Nunes Ferraz
- Mariana Vallim SallesMSMariana Vallim Salles
- Rebeca Azevedo Souza AmaralRARebeca Azevedo Souza Amaral
- Mariana Matioli da PalmaMPMariana Matioli da Palma
- 24 June 2026
- journal article
- Published by Taylor & Francis in Ophthalmic Genetics
- p. 1-7
Abstract
This study aimed to report the longitudinal Ora Visual Navigation Course (Ora VNC™) mobility test results in two individuals, with CEP290 LCA following intravitreal injections of an antisense oligonucleotide, sepofarsen. Two individuals were enrolled in the Illuminate Phase 3 trial and subsequently in the Post-Trial Access (PTA) program, undergoing Ora VNC™ across 12 visits. Subject 1 was initially randomized to the control (sham) group and switched to treatment from control group from the month 12 visit onwards. This individual passed only a few courses but demonstrated signs of enhanced spatial perception (defined by, among others, the ability to perceive objects' shapes and sizes). FST (full-field stimulus threshold) supported the light sensitivity gain in this subject. In contrast, subject 2, who received treatment since baseline visit, successfully completed mobility tests in all visits with progressive improvement, reaching lower luminance and more challenging contrast settings over time. According to the technicians' report, both subjects demonstrated an increase in perceived obstacle recognition during iterations, which may reflect improvement of mobility-based visual function outcomes. The Ora VNC™ mobility test captured mobility-based visual function gains, including subtle spatial improvements, but may lack sensitivity in individuals with extremely low vision, potentially overlooking small but patient-relevant changes.Keywords
Funding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Finance Code 001)
- ProQR Therapeutics
This publication has 17 references indexed in Scilit:
- Recovery of cone-mediated vision in Lebercilin associated retinal ciliopathy after gene therapy: One-year results of a phase I/II trialMolecular Therapy, 2025
- Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation studyThe Lancet, 2024
- Screening for Autism Spectrum Disorder in Children and Adolescents With Leber's Congenital AmaurosisAmerican Journal of Ophthalmology, 2024
- Multi-luminance mobility testing after gene therapy in the context of retinal functional diagnosticsGraefe's Archive for Clinical and Experimental Ophthalmology, 2023
- Durable vision improvement after a single intravitreal treatment with antisense oligonucleotide in CEP290-LCA: Replication in two eyesAmerican Journal of Ophthalmology Case Reports, 2023
- Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trialNature Medicine, 2022
- Restoration of Cone Sensitivity to Individuals with Congenital Photoreceptor Blindness within the Phase 1/2 Sepofarsen TrialOphthalmology Science, 2022
- Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation–Associated Inherited Retinal DystrophyOphthalmology, 2019
- Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trialThe Lancet, 2017
- Foundations of spatial vision: From retinal images to perceived shapes.Psychological Review, 2000